Clinical Report: Roswell Park Launches Exclusive Phase 1 Clinical Trial of ‘Armored’ CAR T-Cell Therapy for Ovarian Cancer

Overview

Roswell Park Comprehensive Cancer Center is initiating a Phase 1 clinical trial for GB-5267, an 'armored' CAR T-cell therapy targeting MUC16 in ovarian cancer patients. This therapy does not require lymphodepletion prior to T-cell infusion.

Background

Ovarian cancer is challenging to treat, especially in cases of relapse or resistance to standard platinum-based chemotherapy. CAR T-cell therapies have been effective in hematologic malignancies, but their use in solid tumors like ovarian cancer has been limited. The development of GB-5267 addresses these challenges.

Data Highlights

Currently recruiting for Phase 1 clinical trial (NCT07489287).

Key Findings

• GB-5267 targets the MUC16 antigen, over-expressed in more than 80% of ovarian tumors.
• The therapy is designed to activate T cells, enhance their persistence, and recruit endogenous immune cells.
• GB-5267 will be administered both intravenously and directly into the peritoneal cavity.
• This CAR T-cell therapy does not require lymphodepletion, reducing chemotherapy-related side effects.
• Relapsed/refractory ovarian cancer has a five-year relative survival rate of only 51.6%.

Clinical Implications

GB-5267 may provide a new treatment option for patients with relapsed or refractory ovarian cancer.

Conclusion

The Phase 1 trial of GB-5267 is a step forward in the treatment of ovarian cancer.

Related Resources & Content

1. Roswell Park Comprehensive Cancer Center, Clinical Trial Offers CAR T-Cell Therapy Targeting MUC16 for Recurrent/Refractory Ovarian Cancer, 2023 -- https://physicianresources.roswellpark.org/news/clinical-trial-offers-car-t-cell-therapy-targeting-muc16-for-recurrent/refractory-ovarian-cancer
2. Roswell Park Comprehensive Cancer Center, Roswell Park Accelerates CAR T-Cell Innovation with Upcoming Trials, 2023 -- https://physicianresources.roswellpark.org/videos/roswell-park-accelerates-car-t-cell-innovation-with-upcoming-trials
3. Roswell Park Comprehensive Cancer Center, First-in-Human Clinical Trial for B-cell Lymphoma Using “Armored” CAR T Cells Opens at Roswell Park, 2023 -- https://physicianresources.roswellpark.org/videos/first-in-human-clinical-trial-for-b-cell-lymphoma-using-armored-car-t-cells-opens-at-roswell-park
4. ESMO Clinical Practice Guideline Express Update on the management of epithelial ovarian cancer, 2026 -- https://pmc.ncbi.nlm.nih.gov/articles/PMC12947637/?utm_source=openai
5. Clinical Trials Using Anti-MUC16 CAR T-cells 27T51, NCI -- https://www.cancer.gov/research/participate/clinical-trials/intervention/anti-muc16-car-t-cells-27t51?pn=1&utm_source=openai
6. roswell park comprehensive cancer center — Clinical Trial Offers CAR T-Cell Therapy Targeting MUC16 for Recurrent/Refractory Ovarian Cancer
7. roswell park comprehensive cancer center — Roswell Park Accelerates CAR T-Cell Innovation with Upcoming Trials
8. roswell park comprehensive cancer center — First-in-Human Clinical Trial for B-cell Lymphoma Using “Armored” CAR T Cells Opens at Roswell Park
9. roswell park comprehensive cancer center — Roswell Park Set to Open Several New Trials this Year for Innovative CAR T-Cell Therapies
10. ESMO Clinical Practice Guideline Express Update on the management of epithelial ovarian cancer - PMC
11. Clinical Trials Using Anti-MUC16 CAR T-cells 27T51 - NCI
12. Current strategies for armoring chimeric antigen receptor T-cells to overcome barriers of the solid tumor microenvironment - PubMed